Healthcare Sector Review: Winning and Losing Stocks on Oct 20th

Wall St. Watchdog reveals information about today’s action in the Healthcare (NYSE:XLV) sector:

Gainers (% price change)

  • Amylin Pharmaceuticals (NASDAQ:AMLN): The shares closed at $11.55, up $1.31, or 12.79%, on the day. Its market capitalization is $1.69 billion. About the company: Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes.
  • Dynavax Tech. Corp. (NASDAQ:DVAX): The shares closed at $2.76, up $0.25, or 9.96%, on the day. Its market capitalization is $340.63 million. About the company: Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
  • Optimer Pharmaceuticals (NASDAQ:OPTR): The shares closed at $14.48, up $1.27, or 9.61%, on the day. Its market capitalization is $674.82 million. About the company: Optimer Pharmaceuticals, Inc. discovers, develops, and commercializes anti infective products. Optimer’s initial development efforts address products that treat gastrointestinal infections (GI), and related diseases, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance, and bacterial resistance.
  • Cubist Pharmaceuticals (NASDAQ:CBST): The shares closed at $39.92, up $3.5, or 9.61%, on the day. Its market capitalization is $2.44 billion. About the company: Cubist Pharmaceuticals, Inc. is a drug company that discovers, develops, and commercializes novel drugs to treat infections. The Company’s lead product is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections.
  • Halozyme Therapeutics (NASDAQ:HALO): The shares closed at $7.72, up $0.53, or 7.37%, on the day. Its market capitalization is $799.94 million. About the company: Halozyme Therapeutics, Inc. develops and commercializes recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The Company’s product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme’s products offer an alternative to slaughterhouse-derived extracts that carry contamination risks.

Losers (% price change)

  • Inhibitex, Inc. (NASDAQ:INHX): The shares closed at $3.35, down $0.36, or 9.7%, on the day. Its market capitalization is $261.92 million. About the company: Inhibitex Inc. is a biopharmaceutical company that discovers, develops, and commercializes novel antibody-based products. The Company develops products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting.
  • NPS Pharmaceuticals, Inc. (NASDAQ:NPSP): The shares closed at $6.74, down $0.4, or 5.6%, on the day. Its market capitalization is $579.89 million. About the company: NPS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.
  • Enzo Biochem, Inc. (NYSE:ENZ): The shares closed at $2.61, down $0.14, or 5.09%, on the day. Its market capitalization is $100.72 million. About the company: Enzo Biochem, Inc. researches, develops, and manufactures health care products based on molecular biology and genetic engineering techniques. The Company also provides diagnostic services to the medical community. Enzo Biochem’s labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world.
  • Human Genome Sciences (NASDAQ:HGSI): The shares closed at $13.30, down $0.68, or 4.86%, on the day. Its market capitalization is $2.54 billion. About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.
  • Orexigen Therapeutics (NASDAQ:OREX): The shares closed at $2.09, down $0.1, or 4.57%, on the day. Its market capitalization is $100.50 million. About the company: Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system, or CNS, disorders with an initial focus on obesity.

(Note: Selected financial data are sourced from Google Finance. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>